Sharyn M Fitzgerald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8062417/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing Events in the Elderly Study and Its Predictive Capacity for Disability-Free Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 19-26.	3.6	20
2	The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2007-2014.	3.6	9
3	Quality of life after stroke: a longitudinal analysis of a cluster randomized trial. Quality of Life Research, 2022, 31, 2445-2455.	3.1	8
4	Prediction of disability-free survival in healthy older people. GeroScience, 2022, 44, 1641-1655.	4.6	7
5	Sleepâ€disordered breathing was associated with lower healthâ€related quality of life and cognitive function in a crossâ€sectional study of older adults. Respirology, 2022, 27, 767-775.	2.3	7
6	Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. Molecular Psychiatry, 2021, 26, 5161-5170.	7.9	18
7	Social isolation, social support, loneliness and cardiovascular disease risk factors: A crossâ€sectional study among older adults. International Journal of Geriatric Psychiatry, 2021, 36, 1795-1809.	2.7	28
8	Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Journal of the American Geriatrics Society, 2021, 69, 3568-3575.	2.6	0
9	443Factors associated with frailty in a relatively healthy community-dwelling older adults. International Journal of Epidemiology, 2021, 50, .	1.9	0
10	Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2007-2014.	3.6	13
11	Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. American Journal of Hypertension, 2020, 33, 350-361.	2.0	5
12	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. Journal of Hypertension, 2020, 38, 2527-2536.	0.5	3
13	Effect of Aspirin vs Placebo on the Prevention of Depression in Older People. JAMA Psychiatry, 2020, 77, 1012.	11.0	47
14	Recruiting general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (<scp>ASPREE</scp>) study. Medical Journal of Australia, 2019, 210, 168-173.	1.7	28
15	The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study. Contemporary Clinical Trials, 2018, 64, 101-111.	1.8	12
16	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1499-1508.	27.0	392
17	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1519-1528.	27.0	591
18	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1509-1518.	27.0	770

#	Article	IF	CITATIONS
19	Effectiveness of an Intervention to Improve Risk Factor Knowledge in Patients With Stroke. Stroke, 2017, 48, 1101-1103.	2.0	10
20	Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1586-1593.	3.6	143
21	Long-term unmet needs and associated factors in stroke or TIA survivors. Neurology, 2017, 89, 68-75.	1.1	44
22	Community-Based Intervention to Improve Cardiometabolic Targets in Patients With Stroke. Stroke, 2017, 48, 2504-2510.	2.0	26
23	Nurse-Led Intervention to Improve Knowledge of Medications in Survivors of Stroke or Transient Ischemic Attack: A Cluster Randomized Controlled Trial. Frontiers in Neurology, 2016, 7, 205.	2.4	6
24	Maximizing Patient Recruitment and Retention in a Secondary Stroke Prevention Clinical Trial: Lessons Learned from the STAND FIRM Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1371-1380.	1.6	5
25	Risk Factor Management in Survivors of Stroke: A Double-Blind, Cluster-Randomized, Controlled Trial. International Journal of Stroke, 2014, 9, 652-657.	5.9	16
26	Gender-specific effects of caste and salt on hypertension in poverty: a population-based study. Journal of Hypertension, 2011, 29, 443-450.	0.5	21
27	Potential roles of high salt intake and maternal malnutrition in the development of hypertension in disadvantaged populations. Clinical and Experimental Pharmacology and Physiology, 2010, 37, e78-90.	1.9	26
28	Glomerular surface area is normalized in mice born with a nephron deficit: no role for AT1 receptors. American Journal of Physiology - Renal Physiology, 2009, 296, F583-F589.	2.7	11
29	Benefits and Challenges in Stroke Research in Developing Countries. Brain Impairment, 2008, 9, 198-204.	0.7	2
30	Combined prenatal and postnatal protein restriction influences adult kidney structure, function, and arterial pressure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R462-R469.	1.8	102
31	Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1072-H1082.	3.2	21
32	Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarizing factor. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R707-R713.	1.8	33
33	Platelet-derived growth factor B retention is essential for development of normal structure and function of conduit vessels and capillariesâ~†. Cardiovascular Research, 2006, 71, 557-565.	3.8	37
34	Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoEâ^'/â^' mice. Journal of Hypertension, 2005, 23, 1541-1549.	0.5	28
35	Nitric oxide and superoxide in the renal medulla: a delicate balancing act. Current Opinion in Nephrology and Hypertension, 2005, 14, 9-15.	2.0	58
36	ROLE OF ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR IN ENDOTHELIAL DYSFUNCTION DURING DIABETES. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 482-487.	1.9	46

#	Article	IF	CITATIONS
37	Decreased RhoA expression in myocardium of diabetic rats. Canadian Journal of Physiology and Pharmacology, 2005, 83, 775-783.	1.4	5
38	Bovine Growth Hormone Transgenic Mice Are Resistant to Diet-Induced Obesity but Develop Hyperphagia, Dyslipidemia, and Diabetes on a High-Fat Diet. Endocrinology, 2005, 146, 920-930.	2.8	74
39	Reduced Exercise Endurance in Interleukin-6-Deficient Mice. Endocrinology, 2004, 145, 2680-2686.	2.8	120
40	Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. Journal of Clinical Investigation, 2004, 113, 1560-1570.	8.2	175
41	Cardiovascular and renal phenotyping of genetically modified mice: A challenge for traditional physiology. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 207-216.	1.9	19
42	Liver-Derived Insulin-Like Growth Factor-I Is Involved in the Regulation of Blood Pressure in Mice. Endocrinology, 2002, 143, 4235-4242.	2.8	65
43	Hypertension in <scp>l</scp> -NAME-treated diabetic rats depends on an intact sympathetic nervous system. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R1070-R1076.	1.8	19
44	Blood Pressure Control Early In Diabetes: A Balance Between Angiotensin Ii And Nitric Oxide. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 127-131.	1.9	21
45	Cardiovascular and renal responses to a high-fat diet in Osborne-Mendel rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R547-R552.	1.8	35
46	Nitric oxide may be required to prevent hypertension at the onset of diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E762-E768.	3.5	35
47	Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vasoconstriction. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E917-E924.	3.5	21
48	Renal Hemodynamic Responses to Intrarenal Infusion of Ligands for the Putative Angiotensin IV Receptor in Anesthetized Rats. Journal of Cardiovascular Pharmacology, 1999, 34, 206-211.	1.9	39
49	EFFECTS OF LONG-TERM EXTRARENAL ANGIOTENSIN II INFUSION ON RENAL VASCULAR RESPONSIVENESS TO VASOACTIVE AGENTS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 633-636.	1.9	0
50	Acute Endothelium-Mediated Vasodilation Is Not Impaired at the Onset of Diabetes. Hypertension, 1998, 32, 541-547.	2.7	32
51	Low Dose Angiotensin II Infusions into the Renal Artery Induce Chronic Hypertension in Conscious Dogs. Blood Pressure, 1997, 6, 52-61.	1.5	13
52	Systemic hemodynamic responses to chronic angiotensin II infusion into the renal artery of dogs. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1997, 273, R1980-R1989.	1.8	6
53	CHRONIC INTRARENAL INFUSION OF LOW-DOSE ANGIOTENSIN II IN DOGS INCREASES ARTERIAL PRESSURE WITHOUT IMPAIRMENT OF RENAL FUNCTION. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 439-441.	1.9	4
54	RENAL EFFECTS OF RILMENIDINE IN VOLUME-LOADED ANAESTHETIZED DOGS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 64-67.	1.9	5

#	Article	IF	CITATIONS
55	Chronic renal blood flow measurement in dogs by transit-time ultrasound flowmetry. Journal of Pharmacological and Toxicological Methods, 1997, 38, 33-39.	0.7	7
56	Nitric Oxide Synthase Blockade and Renal Vascular Responses to Norepinephrine and Endothelin-1 in Conscious Dogs. Journal of Cardiovascular Pharmacology, 1995, 25, 979-985.	1.9	11